Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice.

Stimulation of cardiac beta1-adrenergic receptors is the main mechanism that increases heart rate and contractility. Consequently, several pharmacological and gene transfer strategies for the prevention of heart failure aim at improving the function of the cardiac beta-adrenergic receptor system, whereas current clinical treatment favors a reduction of cardiac stimulation. To address this controversy, we have generated mice with heart-specific overexpression of beta1-adrenergic receptors. Their cardiac function was investigated in organ bath experiments as well as in vivo by cardiac catheterization and by time-resolved NMR imaging. The transgenic mice had increased cardiac contractility at a young age but also developed marked myocyte hypertrophy (3.5-fold increase in myocyte area). This increase was followed by progressive heart failure with functional and histological deficits typical for humans with heart failure. Contractility was reduced by approximately 50% in 35-week-old mice, and ejection fraction was reduced down to a minimum of approximately 20%. We conclude that overexpression of beta1-adrenergic receptors in the heart may lead to a short-lived improvement of cardiac function, but that increased beta1-adrenergic receptor signalling is ultimately detrimental.

[1]  M. Böhm,et al.  Reduction of beta-adrenoceptor density and evaluation of positive inotropic responses in isolated, diseased human myocardium. , 1988, European heart journal.

[2]  O. Brodde Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. , 1991, Pharmacological reviews.

[3]  R. Lefkowitz,et al.  Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. , 1994, Science.

[4]  Stefan Neubauer,et al.  Magnetic resonance microimaging for noninvasive quantification of myocardial function and mass in the mouse , 1998, Magnetic resonance in medicine.

[5]  G. Dorn,et al.  Decompensation of Pressure-Overload Hypertrophy in Gαq-Overexpressing Mice , 1998 .

[6]  R. Lefkowitz,et al.  Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[7]  L. Brunton,et al.  Direct analysis of beta-adrenergic receptor subtypes on intact adult ventricular myocytes of the rat. , 1985, Circulation research.

[8]  J. Fewell,et al.  Transgenic remodeling of the contractile apparatus in the mammalian heart. , 1996, Circulation research.

[9]  M. Michel,et al.  Myocardial beta-adrenoceptor changes in heart failure: concomitant reduction in beta 1- and beta 2-adrenoceptor function related to the degree of heart failure in patients with mitral valve disease. , 1989, Journal of the American College of Cardiology.

[10]  M. Lohse,et al.  Molecular mechanisms of membrane receptor desensitization. , 1993, Biochimica et biophysica acta.

[11]  G. Barsh,et al.  Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Böhm,et al.  Analysis of beta-adrenergic receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reactions: progressive reduction of beta 1-adrenergic receptor mRNA in heart failure. , 1996, Journal of the American College of Cardiology.

[13]  D C Harrison,et al.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. , 1982, The New England journal of medicine.

[14]  M. Böhm,et al.  Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. , 1993, Circulation.

[15]  M. Caron,et al.  Cloning of the cDNA for the human beta 1-adrenergic receptor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[16]  H. Katus,et al.  Transgenic animal models: new avenues in cardiovascular physiology , 1997, Journal of Molecular Medicine.

[17]  R. Lefkowitz,et al.  Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Bouvier,et al.  Distinct regulation of beta 1- and beta 2-adrenergic receptors in Chinese hamster fibroblasts. , 1992, Molecular pharmacology.

[19]  G. Barsh,et al.  Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Lefkowitz,et al.  Mitogenic signaling via G protein-coupled receptors. , 1996, Endocrine reviews.

[21]  R. Lefkowitz,et al.  Ligand-induced overexpression of a constitutively active beta2-adrenergic receptor: pharmacological creation of a phenotype in transgenic mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  E. Lakatta,et al.  Beta 2-adrenergic receptor-stimulated increase in cAMP in rat heart cells is not coupled to changes in Ca2+ dynamics, contractility, or phospholamban phosphorylation. , 1994, The Journal of biological chemistry.

[23]  M. Packer,et al.  Neurohormonal interactions and adaptations in congestive heart failure. , 1988, Circulation.

[24]  S. Vatner,et al.  Myocardial beta-adrenergic receptor function during the development of pacing-induced heart failure. , 1993, The Journal of clinical investigation.

[25]  L. Birnbaumer,et al.  Efficacy of beta 1-adrenergic receptors is lower than that of beta 2-adrenergic receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.